Registration Document Including the Annual Financial Report

The report describes Transgene’s 2018 progress across five clinical products and expansion of its Invir.IO oncolytic-virus platform. It highlights the launch of myvac, a personalized vaccine platform, and a strategic collaboration with NEC using artificial intelligence to select tumor neoantigens; two TG4050 clinical studies were planned. Transgene also transferred Greater China rights to Tasly in exchange for shares valued at $48 million.